Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
Фаза 3
Прекращено
NCT05223673
| Заболевание | Metastatic Colorectal Cancer |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Institut de Recherches Internationales Servier |
|---|
| Статус | Прекращено |
|---|
| Участники | 7 участн. |
|---|
| Вмешательство | Futuximab/modotuximab, Trifluridine/Tipiracil, Trifluridine/Tipiracil |
|---|
| Дата начала | 21.04.2022 |
|---|
| Дата завершения | 21.06.2023 |
|---|
| Публикация результатов | 5.03.2024 |
|---|
Кратко
This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF agents and anti-EGFR antibodies. The main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. The primary objective of the phase III part is to compare Overall Survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are KRAS/NRAS and BRAF wild-type (WT).
Incidence of Dose-limiting Toxicities (DLTs) (Safety Lead-In Part)
End of cycle 1 (Each cycle is up to 28 days) · dose-limiting toxicities (DLTs)
| Futuximab/Modotuximab Combined With Trifluridine/Tipiracil (Safety Lead-In and Phase III Parts) | 0 dose-limiting toxicities (DLTs) |
|---|
Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)
up to 4 years 9 months
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.